Table 2 Utility cost and value
| Â | Costs ($AUD) | Source from Medicare Benefits Schedule (MBS [33]) | Utility value [31] |
|---|---|---|---|
Disease-free state | Â | Â | 0.832 |
CT surveillance (per visit) | 340 | MBS item 56,107 | Â |
MRI surveillance (per visit) | 867 | MBS item 15,559 | Â |
PET surveillance (per visit) | 999 | MBS item 61,646 | Â |
Undetected local recurrence | Â | Â | 0.752 |
Undetected oligometastasis | Â | Â | 0.655 |
Detected local recurrence (year 1) | 7501 | 50% myocutaneous flap (MBS item no. 45,006) + 4 bed-days = $1038 + 4 × $1038 = $5190 50% free tissue transfer (MBS 45,564) + 7 day LoS = $2546 + 7 × $1038 = $9812 | 0.655 |
Detected local recurrence (year 2) | 3043 | Annual cost: Three consultations (MBS 104), chest X-rays (MBS 58,506) and MRIs = 3 × ($86.85 + $60.75 + $867) | 0.752 |
Detected oligometastasis (year 1) | 9945 | Lung wedge resection (MBS 38,440) + pneumonectomy or lobectomy or segmentectomy (MBS 38,438) + 7 day LoS = $1147 + $1532 + 7 × $1038 | 0.655 |
Detected oligometastasis (year 2) | 3258 | Annual cost: Three consultations and full-body PET scans = 3 × ($86.85 + $999) | 0.655 |
Detected polymetastasis (year 1) | 63,284 | Reported expected lifetime cost divided by 3Â year expected survival [40] | 0.443 |